

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

1-28. Canceled

29. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the method does not include treatment with a radiolabeled anti-CD20 antibody.
30. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.001 to about 30 mg/kg.
31. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.01 to about 25 mg/kg.
32. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.1 to about 20 mg/kg.
33. (Previously presented) A method according to claim 29, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 375 mg/m².
34. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 to about 1500 mg/m², wherein the method does not include treatment with a radiolabeled anti-CD20 antibody.

35. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 mg/m².
36. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 650 mg/m².
37. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 825 mg/m².
38. (Previously presented) A method according to claim 34, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 1500 mg/m².
39. (Previously presented) A method according to claim 29 or 34, wherein the patient has relapsed following previous treatment for the chronic lymphocytic leukemia.
40. (Previously presented) A method according to claim 29 or 34, wherein the patient is refractory to a treatment previously administered for the chronic lymphocytic leukemia.
41. (Previously presented) A method according to claim 40, wherein the patient is refractory to fludarabine.
42. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a chimeric antibody.
43. (Previously presented) A method according to claim 42, wherein the anti-CD20 antibody is rituximab.
44. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a humanized antibody.

45. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is a human antibody.
46. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody comprises a CD20-binding fragment of a chimeric, humanized, or human antibody.
47. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is administered to the patient repeatedly.
48. (Previously presented) A method according to claim 47, wherein the repeated administration comprises a stepped-up dosing schedule.
49. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient weekly.
50. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient weekly for about 2 to 10 weeks.
51. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient biweekly.
52. (Previously presented) A method according to claim 47, wherein the anti-CD20 antibody is administered to the patient monthly.
53. (Previously presented) A method according to claim 29 or 34, wherein the anti-CD20 antibody is administered to the patient parenterally.
54. (Previously presented) A method according to claim 53, wherein the anti-CD20 antibody is administered to the patient by intravenous infusion.

55. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody therapy is combined with chemotherapy, wherein the method does not include treatment with a radiolabeled anti-CD20 antibody.
56. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.001 to about 30 mg/kg.
57. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.01 to about 25 mg/kg.
58. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.1 to about 20 mg/kg.
59. (Previously presented) A method according to claim 55, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 375 mg/m².
60. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 to about 1500 mg/m², [[and]] wherein the anti-CD20 antibody therapy is combined with chemotherapy, and wherein the method does not include treatment with a radiolabeled anti-CD20 antibody.
61. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 mg/m².

62. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 650 mg/m².
63. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 825 mg/m².
64. (Previously presented) A method according to claim 60, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 1500 mg/m².
65. (Previously presented) A method according to claim 55 or 60, wherein the patient has relapsed following previous treatment for the chronic lymphocytic leukemia.
66. (Previously presented) A method according to claim 55 or 60, wherein the patient is refractory to a treatment previously administered for the chronic lymphocytic leukemia.
67. (Previously presented) A method according to claim 66, wherein the patient is refractory to fludarabine.
68. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a chimeric antibody.
69. (Previously presented) A method according to claim 68, wherein the anti-CD20 antibody is rituximab.
70. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a humanized antibody.
71. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is a human antibody.

72. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody comprises a CD20-binding fragment of a chimeric, humanized, or human antibody.
73. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is administered to the patient repeatedly.
74. (Previously presented) A method according to claim 73, wherein the repeated administration comprises a stepped-up dosing schedule.
75. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient weekly.
76. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient weekly for about 2 to 10 weeks.
77. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient biweekly.
78. (Previously presented) A method according to claim 73, wherein the anti-CD20 antibody is administered to the patient monthly.
79. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody is administered to the patient parenterally.
80. (Previously presented) A method according to claim 79, wherein the anti-CD20 antibody is administered to the patient by intravenous infusion.
81. (Previously presented) A method according to claim 55 or 60, wherein the anti-CD20 antibody therapy and the chemotherapy are administered to the patient concurrently.

82. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises chlorambucil.
83. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises cyclophosphamide.
84. (Previously presented) A method according to claim 83, wherein the chemotherapy comprises cyclophosphamide, vincristine, and prednisone (COP).
85. (Previously presented) A method according to claim 83, wherein the chemotherapy comprises cyclophosphamide, vincristine, prednisone, and doxorubicin (CHOP).
86. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises vincristine.
87. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises prednisone.
88. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises doxorubicin.
89. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises fludarabine.
90. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises methotrexate.
91. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises cisplatin.

92. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises toremifene.
93. (Previously presented) A method according to claim 55 or 60, wherein the chemotherapy comprises tamoxifen.
94. (Currently amended) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the patient is refractory to fludarabine previously administered for the chronic lymphocytic leukemia, and wherein the method does not include treatment with a radiolabeled anti-CD20 antibody.
95. Canceled
96. (Previously presented) A method according to claim 34, 60, or 94, wherein radiation is not used in conjunction with the anti-CD20 antibody.
97. (Previously presented) A method of treating chronic lymphocytic leukemia in a human patient, comprising administering a therapeutic anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein radiation is not used in conjunction with the therapeutic anti-CD20 antibody.
98. Canceled.